Health Canada confirmed that it approved the semaglutide injection following a comprehensive evaluation of safety, efficacy, and quality standards. The authorisation applies to the same once-weekly treatment protocol used for managing Type-2 diabetes as the branded Ozempic.
The approval comes after the expiration of semaglutide patent protections in Canada earlier this year, opening the market to generic competition. Industry analysts describe this development as a crucial test case for how generic manufacturers may challenge branded peptide-based therapies in advanced markets.
Following the regulatory clearance, Dr Reddy’s is expected to scale up production and supply millions of doses upon commercial launch. The company’s stock reflected investor attention, trading at Rs 1,339.90 at the time of reporting, registering a decline of 0.8 percent. The approval builds on earlier generic clearances secured by the company in India and other emerging markets.
In Canada, generic semaglutide is projected to be priced 45 to 90 percent lower than the original Ozempic, in line with Health Canada pricing norms. Multiple additional applications for generic versions remain under review, indicating an increasingly competitive market landscape.
Globally, pharmaceutical companies are intensifying efforts to introduce lower-cost alternatives to semaglutide and other GLP-1 therapies. Analysts anticipate that in highly competitive environments, monthly treatment costs could fall to as low as 14 US dollars, approximately Rs 1,323.
In India, the launch of generic semaglutide has already ignited aggressive competition. Companies such as Natco Pharma and Alkem Laboratories are offering significantly discounted versions. Natco Pharma has introduced its product at around Rs 1,290 per month, while Alkem Laboratories is promoting weekly pricing strategies equivalent to approximately Rs 450 per week to attract cost-sensitive consumers.
Industry sources indicate that these developments signal the beginning of a price war within the GLP-1 segment, with pharmaceutical firms competing for market share through affordability and accessibility. The anticipated entry of additional players is expected to exert further downward pressure on prices.
The broader impact on consumers is expected to be substantial. Lower-cost generic semaglutide could significantly reduce out-of-pocket expenses for patients managing diabetes and those using the drug for weight loss. Previously, high costs in markets such as Canada and the United States limited access to affluent segments of the population.
Improved affordability is likely to expand treatment access to a wider patient base, including individuals with diabetes, obesity, and metabolic disorders. Enhanced accessibility may also improve long-term health outcomes by encouraging consistent treatment adherence and enabling earlier intervention.
Healthcare providers and pharmacies in India are expected to witness a surge in demand as prices continue to decline and multiple generic options become available. However, medical experts emphasise that increased accessibility must be accompanied by proper clinical supervision and patient education to ensure safe and effective use, particularly in weight management applications.
The approval of a generic version of Ozempic in a major developed market represents a turning point for the global pharmaceutical industry, potentially reshaping pricing structures, expanding access to critical therapies, and intensifying competition in one of the fastest-growing drug segments.
About The Author
Comment List